يتطور
سياسة·30/6/2026ملخص الذكاء الاصطناعي
美国众议院委员会调查两家药企在华临床试验
美国众议院中国问题特设委员会主席穆勒纳尔致函默沙东和艾伯维两家药企，要求提供在华临床试验的尽职调查信息，特别关注新疆地区及军方医院。委员会担忧中国临床试验的伦理标准和数据保护，以及生物技术知识产权转移风险。
德
德国之声3 د قراءة
abbvie
مستقر6 خبر6 مصادرآخر تحديث: 30/6/2026
أحدث الأخبار
خبر
30/6/2026ملخص الذكاء الاصطناعي
AbbVie España destaca la innovación y los pilares del sistema sanitario para el bienestar social
AbbVie España subraya la importancia de los profesionales sanitarios, infraestructuras y medicamentos como pilares del sistema de salud. La innovación terapéutica, impulsada por la IA, mejora la calidad de vida, aumenta la productividad y reduce costes, aunque el acceso a nuevos fármacos en Europa es mejorable.
L
La Vanguardia4 د قراءة
يتطور
Business·22/6/2026ملخص الذكاء الاصطناعي
Club's 10 Things to Watch: SpaceX, Abbvie, CRH, and More
The Club's 10 things to watch include SpaceX initiated with a hold rating, Abbvie's $10.9B acquisition of Apogee Therapeutics, CRH's $8.5B acquisition of Arcosa, and analyst upgrades for Corning, Nucor, and Estee Lauder. Wells Fargo sees further upside in semiconductor capital equipment stocks.
C
CNBC3 د قراءة
يتطور
Business·22/6/2026ملخص الذكاء الاصطناعي
Abbvie kauft Apogee Therapeutics für 10,9 Milliarden Dollar
Der US-Pharmakonzern Abbvie übernimmt das Biotechunternehmen Apogee Therapeutics für 10,9 Milliarden Dollar, um seine Medikamenten-Pipeline zu stärken. Die Übernahme sichert Zugang zu vielversprechenden Wirkstoffen, darunter ein Mittel gegen Neurodermitis, das eine Konkurrenz zu Dupixent darstellen könnte.
H
Handelsblatt2 د قراءة
صحة
25/5/2026ملخص الذكاء الاصطناعي
Anvisa aprova novo medicamento para Parkinson avançado no Brasil
A Anvisa aprovou Vyalev, um novo tratamento para Parkinson avançado que combina foscarbidopa e foslevodopa em infusão subcutânea contínua. A terapia visa manter níveis estáveis da medicação, reduzindo oscilações motoras e oferecendo alternativa a pacientes que não respondem a tratamentos orais ou não podem fazer cirurgia.
G
G12 د قراءة
خبر
18/5/2026ملخص الذكاء الاصطناعي
India Denies Secondary Patent for AbbVie's Hepatitis C Drug Maviret
The Indian Patent Office denied AbbVie a secondary patent for its Hepatitis C drug Maviret, ensuring affordable treatment access for millions. AbbVie abandoned its application after failing to contest oppositions.
E
Economic Times1 د قراءة